Scalper1 News
Teva Pharmaceutical (TEVA) confirmed reports Monday that it will buy Allergan’s (AGN) generic drugs business for $40.5 billion and dropped its hostile takeover bid for Mylan Pharmaceuticals (MYL). Under the deal, Teva will pay $33.75 billion in cash and $6.75 billion in shares. The deal is expected to close in Q1 2016. Teva said the buyout will boost adjusted earnings per share by double-digits in 2016. The deal will allow Allergan to focus on its Scalper1 News
Scalper1 News